Key statistics dashboard for Cocrystal Pharma, Inc. (COCP). Valuation multiples (P/E, P/B, EV/EBITDA), profitability margins, financial-health ratios, per-share metrics and stock-level data in one consolidated view — the snapshot quantitative analysts and value investors check first.
Cocrystal Pharma, Inc. (COCP) is a biotechnology firm dedicated to researching and advancing antiviral treatments for severe and/or persistent viral illnesses. The company leverages structure-based technologies to create new antiviral medications, primarily focusing on infections caused by the hepatitis C virus (HCV), influenza, coronaviruses, and noroviruses.
Stock Data
| Price | $1.14 |
| Market Cap | $16M |
| Enterprise Value | $14.9M |
| Beta | 1.18 |
| Exchange | NASDAQ |
| Country | US |
Valuation Multiples
| P/E Ratio | -1.48 |
| Price / Book | 15.06 |
| P/S | 47.63 |
| EV/EBITDA | -1.57 |
| EV/Sales | 45.12 |
| EV/FCF | -1.83 |
| P/FCF | -1.93 |
| Earnings Yield | -63.23% |
| FCF Yield | -51.87% |
| Dividend Yield | 0.00% |
Profitability
| Gross Margin | 205.76% |
| EBIT Margin | -3011.52% |
| EBITDA Margin | -2876.67% |
| Operating Margin | -3063.64% |
| Net Margin | -3011.52% |
| Return on Equity | -207.47% |
| Return on Assets | -213.77% |
| Return on Invested Capital | -423.90% |
| Return on Capital Employed | -497.29% |
Financial Health
| Current Ratio | 1.24 |
| Quick Ratio | 1.24 |
| Cash Ratio | 0.83 |
| Debt / Equity | 1.28 |
| Debt / Assets | 28.84% |
| Net Debt / EBITDA | 0.09 |
| Interest Coverage | 0.00 |
Per-Share Data
| Revenue per share | 0.02 |
| Book Value per share | 0.08 |
| Cash per share | 0.16 |
| FCF per share | -0.59 |
| Tangible Book Value per share | 0.08 |
| Dividend per share | 0.00 |
Related companies: BOLT · BRTX · CING · DWTX · EVGN · IMNN · IMRN
Explore sector: Healthcare · Biotechnology
More sections of COCP: Overview · Financials · Valuation · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks